Literature DB >> 10447527

A paired-sibling analysis of the XbaI polymorphism in the muscle glycogen synthase gene.

M Orho-Melander1, P Almgren, T Kanninen, C Forsblom, L C Groop.   

Abstract

AIMS/HYPOTHESIS: We have previously shown an association between a XbaI polymorphism in the muscle glycogen synthase gene (GYS1) and both Type II (non-insulin-dependent) diabetes mellitus and hypertension. Association studies are, however, hampered by the selection of the control group. To circumvent these problems we addressed the same question using a novel genotype discordant paired-sibling approach.
METHODS: We identified 122 sex-matched sib-pairs discordant for the Xba1 polymorphism among a new set of 743 Finnish subjects from 227 families with Type II diabetes and paired analyses were done by McNemar test of symmetry and by permutation tests.
RESULTS: Paired analysis showed that siblings with the A2 variant had more hypertension (p = 0.0067), obesity (p = 0.033) and microalbuminuria (p = 0.031) but not significantly more Type II diabetes (p = 0.27) than siblings with the A1 variant. Siblings with the A2 variant were more often treated by insulin (p = 0.050) or anti-hypertensive medication (p = 0.0060) or both. Diabetic A2 variant carriers had higher triglyceride (p = 0.023) and lower HDL cholesterol (p = 0.0059) concentrations and an earlier age at onset of diabetes (p = 0.022) than diabetic siblings with the A1 variant. In non-diabetic sib-pairs the presence of the A2 variant was associated with higher diastolic (p = 0.0014) blood pressure. Finally, the allele frequency of the XbaI polymorphism differed between 216 randomly chosen unrelated Type II diabetic patients and 115 unrelated healthy control spouses without a family history of Type II diabetes (12.7 vs. 6.5 %, p = 0.013). CONCLUSION/
INTERPRETATION: The A2 allele of the XbaI polymorphism in the GYS1 confers an increased susceptibility to different features of the metabolic syndrome and Type II diabetes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447527     DOI: 10.1007/s001250051282

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  7 in total

1.  Pathogenesis of insulin resistance in type 2 diabetes: a collision between thrifty genes and an affluent environment.

Authors:  L C Groop
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 2.  Candidate genes for type 2 diabetes.

Authors:  Hemang Parikh; Leif Groop
Journal:  Rev Endocr Metab Disord       Date:  2004-05       Impact factor: 6.514

3.  Gene expression profiling of mice with genetically modified muscle glycogen content.

Authors:  Gretchen E Parker; Bartholomew A Pederson; Mariko Obayashi; Jill M Schroeder; Robert A Harris; Peter J Roach
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

4.  Variation in GYS1 interacts with exercise and gender to predict cardiovascular mortality.

Authors:  Jenny Fredriksson; Dragi Anevski; Peter Almgren; Marketa Sjögren; Valeriya Lyssenko; Joyce Carlson; Bo Isomaa; Marja-Riitta Taskinen; Leif Groop; Marju Orho-Melander
Journal:  PLoS One       Date:  2007-03-14       Impact factor: 3.240

5.  Integrative network analysis reveals molecular mechanisms of blood pressure regulation.

Authors:  Tianxiao Huan; Qingying Meng; Mohamed A Saleh; Allison E Norlander; Roby Joehanes; Jun Zhu; Brian H Chen; Bin Zhang; Andrew D Johnson; Saixia Ying; Paul Courchesne; Nalini Raghavachari; Richard Wang; Poching Liu; Christopher J O'Donnell; Ramachandran Vasan; Peter J Munson; Meena S Madhur; David G Harrison; Xia Yang; Daniel Levy
Journal:  Mol Syst Biol       Date:  2015-04-16       Impact factor: 11.429

6.  New insights into impaired muscle glycogen synthesis.

Authors:  Leif Groop; Marju Orho-Melander
Journal:  PLoS Med       Date:  2008-01-29       Impact factor: 11.069

7.  The insertion/deletion variation in the alpha2B-adrenoceptor does not seem to modify the risk for acute myocardial infarction, but may modify the risk for hypertension in sib-pairs from families with type 2 diabetes.

Authors:  Amir Snapir; Mika Scheinin; Leif C Groop; Marju Orho-Melander
Journal:  Cardiovasc Diabetol       Date:  2003-11-24       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.